RNAZ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 20:01):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
Dagens volum	1.04M
Gjennomsnittsvolum	509 146
Markedsverdi	3.97M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00500 (0.83%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

Volum Korrelasjon

Lang: 0.32 (neutral)

Kort: 0.22 (neutral)

Signal:(46.533) Neutral

TransCode Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 Mest negative korrelasjoner
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

TransCode Therapeutics, Korrelasjon - Valuta/Råvare

0.26
( neutral )

0.22
( neutral )

0.00
( neutral )

0.34
( neutral )

-0.84
( strong negative )

-0.21
( neutral )

TransCode Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2023
Omsetning:	$0
Bruttogevinst:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2022
Omsetning:	$0
Bruttogevinst:	$-98 606.00 (0.00 %)
EPS:	$-2 165.71

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.133

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.